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Background: Metabolic risk factors, such as obesity, hypertension, and hyperlipidemia are independent
risk factors for the development of various complications in acute pancreatitis (AP). Hypertriglyceridemia
dose-dependently elicits pancreatotoxicity and worsens the outcomes of AP. The role of hyperglycemia,
as a toxic metabolic factor in the clinical course of AP, has not been examined yet.
Methods: We analyzed a prospective, international cohort of 2250 AP patients, examining associations
between (1) glycosylated hemoglobin (HbA1c), (2) on-admission glucose, (3) peak in-hospital glucose
and clinically important outcomes (mortality, severity, complications, length of hospitalization (LOH),
maximal C-reactive protein (CRP)). We conducted a binary logistic regression accounting for age, gender,
etiology, diabetes, and our examined variables. Receiver Operating Characteristic Curve (ROC) was
applied to detect the diagnostic accuracy of the three variables.
Results: Both on-admission and peak serum glucose are independently associated with AP severity and
mortality, accounting for age, gender, known diabetes and AP etiology. They show a dose-dependentl Medicine, Medical School,
ngary.
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A. Nagy, M.F. Juhasz, A. G€orbe et al. Pancreatology xxx (xxxx) xxxassociation with severity (p < 0.001 in both), mortality (p < 0.001), LOH (p < 0.001), maximal CRP
(p < 0.001), systemic (p < 0.001) and local complications (p < 0.001). Patients with peak glucose
>7 mmol/l had a 15 times higher odds for severe AP and a five times higher odds for mortality. We found
a trend of increasing HbA1c with increasing LOH (p < 0.001), severity and local complications.
Conclusions: On-admission and peak in-hospital glucose are independently and dose-dependently
associated with increasing AP severity and mortality. In-hospital laboratory control of glucose and
adequate treatment of hyperglycemia are crucial in the management of AP.
© 2021 Published by Elsevier B.V. on behalf of IAP and EPC.Introduction
Acute pancreatitis (AP) is the inflammation of the pancreas,
most often caused by alcohol consumption and biliary obstruction
[1]. The incidence of AP is gradually increasing worldwide, now
reported to be 4.6e100/100,000 in the general population [2,3]. The
severity of the condition varies, with most cases being classified as
mild, but in 15e30% and 10e20% of the cases, moderate and severe
disease course will occur, resulting in longer hospitalization, organ
failure (OF) and higher mortality (up to 40% in severe cases) [4e6].
Szentesi et al. demonstrated that obesity, hypertension and
hyperlipidemia are independent risk factors for several complica-
tions in AP. Furthermore, the more components of metabolic syn-
drome are present, the higher the risk for more severe disease
outcomes [7]. A prospective cohort study found that hyper-
triglyceridemia dose-dependently increases the severity and rate of
AP complications [8]. As a next step in filling the gaps of knowledge
regarding the role of toxic metabolic factors in the clinical course,
we set out to examine the outcome parameters of AP in the context
of serum glucose concentration.
Hyperglycemia is an established independent risk factor in
numerous diseases. It independently predicts long-term mortality
and is associated with a worse prognosis in acute myocardial
infarction, irrespective of the presence of diabetes mellitus (DM)
[9,10]. It is also associated with a higher rate of poor functional
outcomes and less successful revascularization after acute ischemic
stroke [11,12]. Furthermore, not only the acute elevations in serum
glucose are of interest e studies describe chronic glucose dysre-
gulation to be prognostic for mortality after acute myocardial
infarction, both in diabetic and non-diabetic patients [13e15]. In AP,
the exact role of glucose dysregulation and its laboratory indicators
is yet to be described. However, of the most widely used AP prog-
nostic scoring systems, two (the Ranson and the Glasgow-Imrie)
include a serum glucose concentration above 10 mmol/L, high-
lighting its potential role and association with severity [16].
Our goal was to examine the presence of dose-dependency
between glucose dysregulation and clinically important outcomes
of AP in a large, multicenter, prospective cohort. In our current
cohort analysis (1) previous glucose homeostasis, as assessed by
glycosylated hemoglobin (HbA1c) levels; and especially (2) serum
glucose levels on admission; and (3) the highest glucose levels
during hospitalization have shown dose-dependent associations
with key clinically important outcomes of AP. We also established
hyperglycemia as an independent and dose-dependent risk factor
for mortality.
Methods
Study design, data source
This study presents a post-hoc analysis of a prospective, international, multi-
centerregistryofAPpatients,maintainedbytheHungarianPancreaticStudyGroup
(HPSG). Participantswere enrolled in theAP registry if they fulfilled thediagnostic2
criteria for AP as per the International Association of Pancreatology/American
PancreaticAssociation(IAP/APA)andHPSGguidelines[17,18].Theywerefollowedup
until the end of their AP associated hospital stay (until oral feedingwas reinstated
without symptomsandwith thenormalizationof laboratoryparameters). A list of
study sites can be found in the supplementary material (Supplementary Fig. 1,





In the present analysis, we included 2250 patients from the total
of 2461 participants in the AP registry with available data on (1)
HbA1c any time during the hospitalization with AP and/or (2) on-
admission serum glucose measurement and/or (3) at least two
serum glucose measurements during hospitalization.
Three variables were taken into account in dividing our exam-
ined cohort into subgroups. To observe the role of the glucose ho-
meostasis preceding the admission with AP e ‘before AP’ (BAP) e
participants were divided into five groups based on their HbA1c:
6.50; 6.51e7.00; 7.01e8.00; 8.01e9.00; 9.01%. To reflect the on-
admission state e ‘on-admission AP’ (OAP) e seven groups were
formed based on on-admission serum glucose levels: 3.99,
4.00e5.99, 6.00e7.79, 7.80e11.09, 11.10e14.99, 15.00e19.99,
20.00 mmol/L. Seven groups were formed based on peak serum
glucose during the hospital staye ‘during AP’ (DAP)e among those
patients who had at least two glucose measurements: 3.99,
4.00e5.99, 6.00e7.79, 7.80e11.09, 11.10e14.99, 15.00e19.99,
20.00 mmol/L. These boundaries were chosen to reflect already
established cut-offs (6.5% and 7% for HbA1c, 4.0 mmol/L, 7.8 mmol/
L and 11.1 mmol/L for glucose, as recommended by the World
Health Organization, as well as American and European DM asso-
ciations/societies [20]), participant and event numbers to maintain
statistical power and equal increments to avoid the possibility of
arbitrary cut-off selection.Representativeness
The distribution of epidemiological data and main outcome
variables (such as severity and mortality) were compared between
the total registry population and our investigated cohort. There
were no significant differences between the total population and
the OAP subcohort, indicating that this population's characteristics
are representative of the general AP population. We found signifi-
cant differences from the total cohort: in the length of hospitali-
zation (LOH) in the BAP subcohort, and in age, LOH, and severity in
the DAP subcohort (glucose values were probably monitored more
closely in more severe cases, and thus often older patients)
(Supplementary Fig. 2, Supplementary Table 2).
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A complete list of collected variables e including data on labo-
ratory parameters, complications, severity and mortality e is pro-
vided in our data quality table in the supplementary material
(Supplementary Table 3). Local complications, systemic complica-
tions and severity were defined according to the revised Atlanta
classification [21].
Glucosemeasured only within the first 24 hourswas accepted as
on-admission glucose level. Venous measurements were preferred
and accounted for most of the on-admission values, but results
from capillary samples were also accepted. HbA1c measured any
time during the hospitalization was accepted for this analysis. 95%
of measurements occurred within 48 hours of hospitalization. On-
admission values were determined from randomly taken samples,
as they usually are, that would mean that they are not fasting
samples e however, most AP patients present after hours-days of
abdominal pain, nausea and lack of appetite. On the other hand,
while most subsequent in-hospital samples are collected early in
the morning, a significant proportion of these patients receives
enteral feeding. To conclude, not being able to reliably distinguish
fasting and non-fasting samples is an inherent limitation of
observational trials of AP.
Statistical analysis
For the descriptive analysis of categorical variables, case number
and percentage were computed, while in the case of continuous
variables, patient number, mean, standard deviation (SD), median,
25% and 75% quartiles (IQR) were calculated. To identify the three
subcohorts' representativeness, we used the Chi-squared test in
case of categorical data, the Student's t-test for normally distributed
variables, and the Mann-Whitney U test for non-normally distrib-
uted variables. In ‘Table 1’, groups with outlying age (Kruskal-Wallis
test) and gender distribution (Fisher exact or Chi-squared test)
were sought as well as trends in AP recurrence (RAP), chronic
pancreatitis (CP), hyperlipidemia, DM in the medical history
(Cochran-Armitage test for trend) and AP episode number among
RAP cases (Jonckheere-Terpstra trend test). The dose-dependent
effects of HbA1c, on-admission and maximum glucose levels on
the investigated outcomes, were tested using the Cochran-
Armitage test for trend (in case of categorical variables) and the
Jonckheere-Terpstra trend test (in case of continuous variables).
Where an overall significant effect was found, a pairwise test of
independence (for nominal variables) or a step-down trend test (for
continuous variables) with Benjamini-Hochberg p-value correc-
tions was performed as a post-hoc test [22]. Since the overall p-
value was significant in case of age in the OAP subcohort, we per-
formed the Dunn posthoc test to identify the outlying group,
applying the above mentioned correction method (Supplementary
Table 5).
To detect the predictive accuracy of HbA1c, on-admission
glucose level and maximum glucose level on the mortality and
severity, the Receiver Operating Characteristic Curve (ROC) was
applied. To check the performance of the classification, we used
Area Under the Curve (AUC) with 95% confidence intervals (CI)
(depending on the AUC value, the accuracy of the test can be
categorized as followed: 0.5e0.6 fail, 0.6e0.7 poor, 0.7e0.8 fair,
0.8e0.9 good and above 0.9 excellent). We calculated the potential
best cut-off value as well. Odds ratios (OR) with 95% CI were
calculated for severe AP cases and mortality. Binary logistic
regression was used to test the independent prognostic role of the
three investigated variables. The model contains the following
parameters in all cases: age, gender, DM, AP etiology and HbA1c,
on-admission glucose level or maximum glucose level. We also3
created univariate models for severity and mortality with the same
parameters, this can be found in our supplementary material
(Supplementary Tables 10 and 11). All calculations were performed
with the statistical software R, version 4.0.2 (R Core Team, 2020,
Vienna, Austria) using the coin (v1.3-4; Hothorn et al., 2008),
rcompanion (v2.3.27; Mangiafico, 2021), DescTools (v0.99.39;
Signorell et al., 2020), PMCMRplus (v1.9.0; Pohlert, 2021) and pROC
(v1.17.0.1; Robin et al., 2011), dunn.test (v1.3.5; Dinno, 2017)
packages.
Box plots of LOH and CRP included in the main body of the
article do not visualize outliers above a certain value to allow for a
better interpretation of the figure. The original figures with all
outliers can be found in the supplementary material
(Supplementary Fig. 3).
Ethical approval
Ethical approval for the registry was granted in 2012 by the
Scientific and Research Ethics Committee of the Medical Research
Council (22,254e1/2012/EKU). The registry protocol was approved
by the institution's human research committee preceding the study
initiation. It complies with the ethical guidelines of the Declaration
of Helsinki, reaffirmed in 2013. All participants provided written,
informed consent for participation.
Study reporting
This study is reported according to the ‘Strengthening the




A total of 2250 AP cases were analyzed. Table 1 contains the
baseline information of participants in each subgroup of all three
subcohorts (BAP, OAP and DAP). A statistically significant trend of
increasing proportion of hyperlipidemia and DM in the medical
history with increasing HbA1c and glucose values was seen in all
subcohorts. Among groups with different on-admission glucose
values, significant age differences were noted, with the highest
mean ages observed in groups 4e6 (glucose 7.8e19.99mmol/L) and
lowest in group 1 (glucose <4 mmol/L).
Etiology distribution
Fig. 1 shows how different etiologies of AP were distributed
across our examined subgroups. While most etiologies showed a
balanced distribution, hypertriglyceridemia (HTG) increased in
higher HbA1c and serum glucose groups, starting at HbA1c >7% in
the BAP, and glucose >11.1 mmol/L in the OAP and DAP subcohorts.
A detailed table of etiology distribution can be found in our sup-
plementary material (Supplementary Table 4).
BAP: pre-existing disturbance of glucose metabolism shows a trend
of increasing AP severity and local complications
While no statistically significant differences were noted
(p ¼ 0.394), a trend of increasing HbA1c and increasing AP severity
was observed. AP severity was highest in Group 4 (21.4% moderate,
5.8% severe). HbA1c was directly associated with the length of
hospitalization (p < 0.001) and maximal CRP (p < 0.001), both
peaking in group 4 probably due to the higher proportion of
moderate cases, but not with mortality, which was the greatest in
Table 1
Baseline characteristics of participants in each group of all three subcohorts. AP: acute pancreatitis; BAP: before AP; OAP: on-admission with AP; DAP: during AP; %: per-
centage; n: number; SD: standard deviation; p: P-value; RAP: recurrent acute pancreatitis; IQR: interquartile range; CP: chronic pancreatitis; DM: diabetes mellitus in the
personal medical history; Hyperlip: hyperlipidemia in the personal medical history.
BAP e HbA1c p
Groups, HbA1c% 6.50 6.51e7.00 7.01e8.00 8.01e9.00 9.01
n (%) 633 (84.0) 28 (3.7) 32 (4.2) 22 (2.9) 39 (5.2)
Age (years), mean (SD) 56.50 (16.76) 63.54 (12.20) 58.38 (12.76) 55.23 (11.59) 53.08 (13.86) 0.068
Female, n (%) 260 (41) 13 (46) 10 (31) 4 (18) 11 (28) 0.078
RAP, n (%) 142 (22) 2 (7) 7 (22) 7 (32) 10 (26) 0.561
Episodes, n, median
(IQR)
138; 1.00 (1.00, 2.00) 2; 1.00 (1.00, 1.00) 6; 1.00 (1.00, 1.00) 7; 1.00 (1.00, 3.50) 10; 1.50 (1.00,
2.75)
0.845
CP, n (%) 48 (8) 3 (11) 3 (9) 2 (9) 2 (5) 0.882
DM, n (%) 74 (11.7) 17 (60.7) 28 (87.5) 18 (81.8) 35 (89.7) <0.001
Hyperlip, n (%) 56 (9) 4 (16) 6 (21) 5 (26) 16 (43) <0.001
OAP e on-admission serum glucose p
Groups, mmol/L 3.99 4e5.99 6.00e7.79 7.80e11.09 11.10e14.99 15.00e19.99 20.00
n (%) 21 (1.0) 468 (22.0) 697 (32.7) 613 (28.8) 221 (10.4) 68 (3.2) 41 (1.9)
Age (years), mean (SD) 45.52 (19.88) 51.40 (17.23) 56.12 (17.62) 59.92 (15.56) 61.20 (14.81) 58.62 (13.91) 53.05 (15.23) <0.001
Female, n (%) 12 (57) 208 (44) 294 (42) 266 (43) 96 (43) 23 (34) 14 (34) 0.423


















CP, n (%) 0 (0) 30 (6) 46 (7) 30 (5) 6 (3) 3 (4) 4 (10) 0.259
DM, n (%) 2 (9.5) 24 (5.1) 62 (8.9) 121 (19.7) 105 (47.5) 49 (72.1) 30 (73.2) <0.001
Hyperlip, n (%) 2 (13) 41 (10) 67 (11) 100 (19) 40 (21) 15 (25) 18 (50) <0.001
DAP e peak serum glucose p
Groups, mmol/L 3.99 4.00e5.99 6.00e7.79 7.80e11.09 11.10e14.99 15.00e19.99 20.00
n (%) 6 (1.0) 187 (31.3) 143 (24.0) 123 (20.6) 79 (13.2) 43 (7.2) 16 (2.7)
Age (years), mean (SD) 60.50 (19.21) 58.03 (18.97) 57.83 (16.13) 59.54 (15.19) 60.82 (13.24) 57.84 (14.44) 61.50 (14.02) 0.844
Female, n (%) 4 (67) 88 (47) 63 (44) 50 (41) 29 (37) 19 (44) 8 (50) 0.611
















CP, n (%) 0 (0) 11 (6) 6 (4) 3 (2) 6 (8) 4 (9) 0 (0) 0.770
DM, n (%) 0 (0) 13 (7.0) 17 (11.9) 28 (22.8) 46 (58.2) 29 (67.4) 10 (62.5) <0.001
Hyperlip, n (%) 2 (33) 18 (12) 21 (18) 19 (17) 23 (31) 13 (33) 6 (40) <0.001
Fig. 1. Etiology distribution. The top row shows the classification of groups. The middle row shows how etiologies within each group (etiologies add up to 100%). The bottom row
shows group distribution within each etiology (groups add up to 100%). AP: acute pancreatitis; BAP: before AP; OAP: on-admission with AP; DAP: during AP; HbA1c: hemoglobin
A1c; Glu: serum glucose; HTG: hypertriglyceridemia; bil: biliary, alc: alcoholic; comb: combined; idiop: idiopathic.
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Fig. 2. AP severity, mortality, length of AP-associated hospital stay, maximal CRP. AP: acute pancreatitis; BAP: before AP; OAP: on-admission with AP; DAP: during AP; HbA1c:
hemoglobin A1c; Glu: serum glucose; LOH: length of AP associated hospitalization; max. CRP: maximal C-reactive protein. Some statisctical outliers were removed (not omitted) in
case of the LOH and max. CRP boxplots to facilitate interpretation, original figures can be found in the supplementary material (Supplementary Fig. 3).
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No trends were identified regarding systemic complications
(respiratory, renal or heart failure) (p ¼ 0.959); the highest rate of
organ failures was found in Group 3 (12.5%) (Fig. 3). On the other
hand, an increasing proportion of local complications (peri-
pancreatic fluid, pancreas pseudocyst, pancreas necrosis) were seen
with increasing HbA1c (Fig. 4), without statistical significance
(p ¼ 0.122).
The binary logistic regression did not show HbA1c to be an in-
dependent predictor of mortality (OR ¼ 1.211 (95% CI:
0.859e1.646), p ¼ 0.241) or severity (OR ¼ 1.028 (95% CI:
0.768e1.332), p ¼ 0.843) (Supplementary Tables 8e9). The ROC
analysis (Supplementary Fig. 4) showed that HbA1c fails to predict5
mortality (AUC ¼ 0.545) and poorly predicts the severity of AP
(AUC ¼ 0.601).OAP and DAP: on-admission and peak glucose levels demonstrate a
dose-dependent association with worse AP outcomes (severity,
mortality, complications, LOH, maximal CRP)
A dose-dependent association was seen between on-admission
glucose levels, peak in-hospital glucose levels and: severity
(p < 0.001 in both OAP and DAP), mortality (p < 0.001 OAP and
DAP), LOH (p < 0.001 OAP and DAP), maximal CRP (p < 0.001 OAP
and DAP) (Fig. 2), systemic complications (p < 0.001 OAP and DAP;
Fig. 3) and local complications (p < 0.001 OAP and DAP; Fig. 4).
Fig. 3. Systemic complications as defined by the revised Atlanta classification and Marshall criteria. The top row shows the classification of groups. The second row shows the
percentage of AP cases with organ failure (one or more of lungs, heart and kidney). The third, fourth, and bottom rows show the percentage of AP cases with respiratory, heart and
renal failure, respectively, in each group. AP: acute pancreatitis; BAP: before AP; OAP: on-admission with AP; DAP: during AP; HbA1c: hemoglobin A1c; Glu: serum glucose.
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7) noted the highest severity (37.5% moderate, 25.0% severe),
mortality (12.5%), systemic (43.8%) and local complications (62.5%).
While similarly, on-admission glucose Group 7 saw the highest rate
of local complications (36.6%), Group 6 (serum glucose
15e19.99 mmol/L) had the highest severity (38.2% moderate, 8.8%
severe), mortality (8.8%), and rate of systemic complications
(14.7%).
The binary logistic regression established both on-admission
and peak in-hospital serum glucose to be independently6
associated with mortality (OR ¼ 1.133 (95% CI: 1.064e1.204),
p < 0.001 and OR ¼ 1.089 (95% CI: 1.020e1.161), p ¼ 0.006,
respectively) and severity (OR ¼ 1.131 (95% CI: 1.078e1.186),
p < 0.001 and OR ¼ 1.093 (95% CI: 1.039e1.152), p < 0.001,
respectively) (Supplementary Tables 8e9). The ROC analysis
(Supplementary Fig. 4) showed on-admission glucose to be a poor
predictor of mortality (AUC ¼ 0.636 for an estimated cut-off of
10.635 mmol/l) and severity (AUC ¼ 0.671 for an estimated cut-off
of 9.435 mmol/l). An on-admission glucose >10 mmol/l had an OR
of 3.140 (95% CI: 2.106e4.682) for severe AP and an OR of 2.666
Fig. 4. Local pancreatic complications as defined by the revised Atlanta classification. The top row shows the classification of groups. The second row shows the percentage of AP
cases with local complications (one or more of acute peripancreatic fluid collection, pancreas pseudocyst, pancreas necrosis e no distinction between acute necrotic collection and
walled-off necrosis). The third, fourth, and bottom rows show the percentage of AP cases with acute peripancreatic fluid collection, pancreas pseudocyst and pancreas necrosis,
respectively, in each group. AP: acute pancreatitis; BAP: before AP; OAP: on-admission with AP; DAP: during AP; HbA1c: hemoglobin A1c; Glu: serum glucose.
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peak in-hospital glucose is a fair predictor of mortality
(AUC¼ 0.703 for an estimated cut-off of 6.665mmol/l) and severity
(AUC ¼ 0.732 for an estimated cut-off of 7.355 mmol/l). A peak in-
hospital glucose >7 mmol/l had an OR of 14.490 (95% CI:
4.443e47.264) for severe AP and an OR of 4.750 (95% CI:
1.370e16.476) for mortality.
Hypoglycemia (Group 1) was associated with a higher rate of
organ failure andmaximal CRP in both the OAP and DAP subcohorts7
and higher severity only in the DAP subcohort. Increased mortality,
LOH or local complications were not seen.
Additional trends, intergroup differences
The results of additional trend tests not discussed in the article's
main body and P-values corresponding to intergroup differences
for all examined outcomes can be found in the supplementary
material (Supplementary Tables 5e7).
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Pancreatic inflammation together with cell death are the end
steps of an intricate interplay of eventse as described by the model
of “multiple hits on multiple targets”, various signaling pathways
are activated resulting in the clinical entity of AP [24]. The main
alterations observed inside the acinar cells are the increase in cal-
cium concentration, increase in the number of lysosomes and
zymogen granules, leading to mitochondrial dysfunction, endo-
plasmic reticulum stress and premature trypsinogen activation [3].
These changes can be initiated either by ductal obstruction [25,26]
or by the direct acinar effect of various pancreatotoxic agents
[27,28]. The most common culprits responsible for pancreatic
toxicity are bile acids, alcohol and its metabolites, but fatty acids
and fatty acid ethyl esters are also described to initiate the above-
mentioned pathways in a dose-dependent manner [27,29e32].
And observations go beyond basic science e cohort studies also
describe hypertriglyceridemia to be dose-dependently associated
with increasing severity and rate of complications [8]. Some drugs
as well and smoking are presumed to directly damage the pancreas
in a dose dependent manner [33,34].
There is a layered relationship between DM and AP. In severe AP
cases with substantial pancreatic necrosis, b-cell loss can lead to the
development of DM [35]. But even in moderate and mild AP,
impaired b-cell function and insulin resistance are observed in
more than 30% of the cases [36], leading to a two-fold risk for
developing diabetes after experiencing a single episode [37,38]. At
the same time, cohort studies described a 1.5e3 times higher risk of
AP among type 2 diabetic individuals e a possible reason behind
this are the overlapping risk factors (e.g., obesity and hyper-
triglyceridemia) [7,39e41]. Another key point in the many in-
tersections between these two conditions is the higher severity of
AP in individuals with pre-existing DM. A meta-analysis of cohort
studies described a significantly higher risk of complications,
intensive care unit (ICU) admission, and mortality as compared to
non-DM individuals [42]. In a pancreatitis rat model,
streptozotocin-induced hyperglycemia significantly reduced the
pancreatic amylase content, which the investigators believed to be
due to the direct harmful effects on acinar cells [43]. This indicates
that glucose itself could be involved in AP as a potential pan-
creatotoxic agent. So far, clinical investigations were limited to
discussing the role of DM e and neglected the glycemic state.
Our study is the first to focus on how alterations of the glucose
homeostasis affect clinically relevant outcomes of AP. We found on-
admission and peak in-hospital serum glucose concentrations to
have a statistically significant dose-dependent relationship with AP
severity, mortality, LOH, maximal CRP, systemic and local compli-
cations. Both these variables are independently (accounting for DM,
age, gender and etiology) associatedwith AP severity andmortality,
a peak in-hospital glucose >7 mmol/l being associated with a 15
times higher likelihood of severe AP and five times higher likeli-
hood of death. While statistically significant dose-dependency was
only identifiedwith LOH andmaximal CRP in case of HbA1c, a trend
of increasing severity and rate of local complications was also
noted. In light of the currently available scientific literature on the
matter, these findings strongly suggest that glucose has a direct
pancreatotoxic effect.
The main step in glucose-mediated cytotoxicity is the intracel-
lular increase in reactive oxygen species (ROS) [44]. ROS also have a
central role in the process of pancreatic inflammation, promoting
pathways towards mitochondrial dysfunction, cell death and
inflammation in a self-amplifying manner [45,46]. Another way in
which glucose could potentially harm the pancreas is via influ-
encing its vasculature. Increased ROS production inside endothelial
cells in hyperglycemia causes microvascular endothelial8
dysfunction by decreasing nitric oxide availability and increasing
permeability, leukocyte adhesion and procoagulant activity [47].
Such microvascular disturbances contribute to the inflammation of
the ischemia-sensitive pancreas [48].
While we demonstrated dose-dependency and independent
association with AP severity and mortality, the whole extent of
worsening AP outcomes should not exclusively be attributed to
glucose. As hyperglycemia often presents in the context of DM and
metabolic syndrome, the prevalence of these conditions accumu-
lates with increasing glucose concentration. Here, an increased rate
of hypertriglyceridemia, cholelithiasis and possibly b-cell hyper-
trophy facilitate the formation of AP [49e52], with hyper-
triglyceridemia also being associated with a more severe disease
course in most studies, although controversy still exists [53e55].
Accordingly, in our cohort, we observed a growing proportion of
hypertriglyceridemia with increasing serum glucose and HbA1c
values. Severity and mortality however, only increased parallelly
with on-admission and peak glucose, but not HbA1c. This might
partly be due to the low participant and event numbers in the
higher HbA1c groupse 83.9% of cases had HbA1c values below 6.5%
- and partly because HbA1c indicates the preceding three months'
glucose homeostasis, not necessarily reflecting glucose levels at the
time of the AP. All in all, the fact that the proportion of hyper-
triglyceridemia increased with all three variables, but severity and
mortality only did so with serum glucose further reinforces the
results of our binary logistic regression, underlining the potential
pancreatotoxic nature of hyperglycemia.
Apart from signaling a transient dysregulation, on-admission
and especially peak in-hospital hyperglycemia could also be
caused by new-onset pancreatogenic DM. A common concern is
that AP episodes that are more severe might have a higher likeli-
hood of substantial b-cell death; this could increase the proportion
of severe cases among those with high glucose values. However,
clinical studies do not support the association between AP severity
and newly diagnosed DM [56]. DM and thus pathological serum
glucose values can be overrepresented in CP cases, 25e80% of CP
patients develop DM [57]. Acute exacerbations in people with CP
are known to be less severe [58], possibly decreasing severity and
mortality in higher HbA1c and glucose groups, but we found a
balanced distribution of CP among groups.
Strengths and limitations
Strengths: To our knowledge, this is the first clinical study
focusing on the role of glucose homeostasis in AP, observing the
presence of dose-dependency with its clinically important out-
comes. We succeeded in demonstrating dose-dependency and in-
dependent association with AP severity and mortality for both on-
admission and peak in-hospital serum glucose. The data source is a
prospective cohort, boasting an impressive number of patients
from multiple centers worldwide, enhancing the applicability of
our results. As described in the 'Methods' section we also applied a
rigorous quality control system, to ensure the validity of our data.
Limitations: A limitation to our study is that glucose values
cannot be separated from the underlying DM and metabolic
comorbidities, possibly influencing outcomes. Nevertheless, we
feel that they should not be separated: although more likely in
diabetic patients, hyperglycemia can occur and elicit pan-
creatotoxicity in any subpopulation. Distinguishing exactly what
causes the dysregulation in each patient was beyond the scope of
this clinically oriented cohort analysis e an interesting question
nonetheless for future studies. Another limitation is that DM is
overrepresented in the BAP subcohort (23.0% of HbA1c measure-
ments happened in known diabetic participants). Only 26.5% of
patients had at least two glucose measurements during their
A. Nagy, M.F. Juhasz, A. G€orbe et al. Pancreatology xxx (xxxx) xxxhospitalization, predominantly those with abnormal on-admission
values (44.7%). As mentioned in the 'Methods' section, capillary
glucose values (although representing the minority of cases) were
also accepted. In an attempt to form groups based on established
cut-offs and equal increments, some groups ended up having
relatively low participant numbers, weakening statistical power.Implications
Prevention: Increased HbA1c was associated with higher
severity and a higher rate of local complications. Maintaining a
normal glucose homeostasis might reduce the risk of these events.
Prognosis: Increased on-admission glucose has a dose-
dependent association with increasing severity, mortality, LOH
and complications of AP.
Prompt treatment: High peak glucose is dose-dependently
associated with a higher rate of severe cases, mortality, systemic
complications and increased LOH. Hyperglycemia does not neces-
sarily present on admission, monitoring serum glucose during the
course of AP is crucial. Adequate in-hospital control of hypergly-
cemia could greatly contribute to the treatment of AP.Author contributions
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